Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Umbralisib shows early promise for patients with marginal zone lymphoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.19
Views: 204

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

Prof Nathan Fowler gives a press conference at AACR 2019 on the results from the UNITY-NHL trial which shows that umbralisib is showing activity and is well tolerated in patients with relapsed/refractory marginal zone lymphoma.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation